February 2026

Week in Review: FDA's alert about J&J heart pumps | $71M in fraud | A new obstacle for heart patients | Lead approved for LBBAP ()
The long-term impact of hypertension during pregnancy | Heart disease, stroke on the rise among women | CCTA delivers value ()
Vascular imaging at heart of $71M fraud scheme | Planning before TAVR | FDA clears platform | Whole-body MRI provider adds CCTA ()
It’s getting harder for heart patients to seek help | New PE guidelines | What cardiologists need to know about Lp(a) ()
FDA shares heart pump warning | Women face rising cardiovascular risks | Alcohol use & CLTI outcomes | 20-year PFO closure data ()
Reprocessed medical devices recalled | CGM sensor issue linked to 860 serious injuries | Managing patients with high-risk leads ()
Potential downsides to AI | Surgery bests GLP-1 drugs | MiniMed seeks $7.9B valuation | AHA launches women's health initiative ()
Statin labels need an update | A new obstacle for Medicare patients | EP catheters recalled | FDA approves lead for LBBAP ()
It’s getting harder to see a cardiologist | 3D echo & young patients | FDA approves pacing lead for LBBAP | TAVR & radiotherapy ()
Cardiologist details benefits of new legislation | A 'striking shift' in TAVR data | Death after PCI | HoFH research ()
Week in Review: TAVR linked to higher reintervention risk | CCTA an essential tool | New PE guidelines | Delaying payment cuts ()
A big update to the Evolut Low Risk trial | Robotic cardiac surgery | Cardiologist develops new device | Tricuspid valve trends ()
New pulmonary embolism guidelines | Gore completes acquisition | Heart failure company files for IPO | Good news for Medtronic ()
5 takeaways from new stroke guidance | J&J devices recalled | Comparing OBLs & ASCs | Atherectomy for CLTI | PAD legislation ()
Cardiologist develops new device | Hypertension & pregnancy | Statin labeling updates | Lawsuit settled | PAD care falling short ()
New-look treatment shows promise | MRI scans evaluate heart failure risk | FDA's heart pump warning | Momentum for CVRx ()
TAVR vs. SAVR: A major update | Medtronic's rising sales | AI for STEMI outcomes | Bill would delay pay cuts | FDA OKs new tech ()
AI calls cath lab patients | New FDA clearances | Medtronic to acquire CathWorks | Murmur detection with digital stethoscopes ()
A growing role for CCTA | CVRx looks ahead | Screening mandates worry cardiologists | Childhood obesity & vascular damage ()
Boston Scientific's $14.5B acquisition | Better pay for office-based interventional labs | Medtronic invests in TAVR tech ()
Top 10 most popular cardiology video interviews this past month ()
Week in Review: Reprocessed catheters recalled | ECG market keeps evolving | Experimental pill impresses | AF Symposium 2026 ()
Choosing PET over SPECT | CCTA & low-risk patients | Medtronic makes a move | Reducing invasive catheterizations | AI for POCUS ()
A major benefit of CCTA | MRI scans for heart failure risk | A fresh approach to redo TAVR planning | Imaging registry expands ()
IVL may be safer than atherectomy | Impella use in elderly patients | Radiation in the cath lab | New-look device makes US debut ()
Key details about Lp(a) | TAVR momentum for Edwards | New scaffold shows promise | Progress for heart catheter | $50M donated ()
TAVR Highlights: Major changes on the way? | Medtronic invests $90M | Judge blocks JenaValve acquisition | New stroke data ()
Reprocessed EP catheters recalled | TAVR outcomes for men & women | The evolving ECG market | Updated instructions | PE research ()
A safety update for cardiologists | AF Symposium 2026 | Catheters recalled | Nasal spray for PSVT | Key FDA approvals ()
News Alert: Reprocessed EP catheters recalled due to contamination risk ()
Boston EP Party: New data presented at AF Symposium 2026 | Where Impella use falls short | A major safety update ()
The fight over cardiologist certification continues | Pioneer heart surgeon elected STS president | Medtronic SVP to retire ()
New cholesterol pill continues to impress | SCAI urges Congress to pass legislation | TAVR valve for AR delivers long-term value ()
Week in Review: FDA's heart pump warning | Medtronic to acquire CathWorks | J&J devices recalled | Comparing CABG strategies ()
Tap water linked to potential risks | Updates on 3 key recalls | Popular diet helps patients live longer | CBD & CVD ()
FDA announces recall of several J&J devices | Survival after SAVR | Treating long femoropopliteal lesions | A new drug recall ()
CGM issue linked to more injuries | Tricuspid valve trends | Medtronic SVP to retire | Best in KLAS | Cardiologist sparks debate ()
Robotic surgery builds momentum | Pioneer surgeon elected STS president | Catheters recalled | A new cardiac care certification ()
FDA's new heart pump warning | Medtronic to acquire CathWorks | Pioneer heart surgeon elected STS president | SCAI takes on ADP ()
January's Top Stories: Trump's aspirin use | New recalls | FDA clears AI tech | TAVR policy changes | Vascular surgeon indicted ()
News Alert: Medtronic to acquire CathWorks for up to $585M ()
STS late-breaker looks at 2 CABG approaches | Key sex differences in 35-year long study | PSVT nasal spray hits US market ()
New-look device implanted for first time in US | IVL vs. atherectomy | How cardiologists can help with noncardiac surgeries ()